The FDA last Friday followed the recommendation of its advisory panel last month (see ARF related news story) and approved memantine for use in moderate to severe AD. Forest Laboratories will sell the drug under the brand name Namenda. Though its effect on cognitive function and activities of daily living is modest, and it probably does not affect the underlying mechanisms causing the disease, memantine nevertheless is the first treatment geared toward more advanced stages of AD. For more information, see FDA press release.—Gabrielle Strobel.
No Available Further Reading